Our Pipeline

Our Pipeline

We are targeting urgent unmet patient needs with our innovative approach.

Wholly-Owned Development Programs
IndicationDiscoveryPreclinicalPhase 1Phase 2
  • Triple-Negative Breast Cancer
  • Clear Cell Renal Cell Carcinoma
  • Head & Neck Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Melanoma

Phase 1

Dose-escalation studyDose-escalation study
Claudin 18.2
  • Gastric Cancer
  • Gastroesophageal Cancer
  • Pancreatic Cancer


IND-enabling studiesIND-enabling studies
Boltbody™ ISAC Collaborations


Funds 3 bispecific Boltbody ISACs through early clinical development


Funds 1 Boltbody ISAC through early clinical development


BDC-3042 is a first-in-class antibody that repolarizes tumor-associated macrophages (TAMs) to attack tumor cells. We identified monoclonal antibodies that are capable of binding to and agonizing Dectin-2, a cell surface protein on tumor-supportive macrophages. The activation of these macrophages results in the production of pro-inflammatory cytokines, consistent with the characteristics of tumor-destructive macrophages. Dectin-2 has the potential to reprogram tumor-supportive macrophages into tumor-destructive macrophages to elicit a productive anti-tumor immune response.

Learn More About BDC-3042


BDC-4182 is Bolt’s next-generation ISAC candidate targeting Claudin 18.2, a novel target in oncology, with programs in development for the treatment of gastric or gastroesophageal junction cancer and pancreatic cancer.